| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/25/2009 | CA2707453A1 Pharmaceutical compositions |
| 06/25/2009 | CA2707422A1 Triazole-substituted arylamide derivatives and their use as p2x3 and /or p2x2/3 purinergic receptor antagonists |
| 06/25/2009 | CA2707010A1 .alpha.-lipoic acid nanoparticles and methods for preparing thereof |
| 06/25/2009 | CA2706839A1 Aminotriazole derivatives as alx agonists |
| 06/25/2009 | CA2706837A1 5-aminocyclylmethyl-oxazolidin-2-one derivatives |
| 06/25/2009 | CA2706836A1 Aminopyrazole derivatives |
| 06/25/2009 | CA2706730A1 Single layered controlled release therapeutic system |
| 06/25/2009 | CA2706655A1 Compositions comprising at least one naphthoic acid derivative and benzoyl peroxide, and at least one film-forming agent methods for preparing same, and uses thereof |
| 06/25/2009 | CA2701150A1 Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof |
| 06/24/2009 | EP2072584A1 Phthalocyanine dyes, their preparation and use |
| 06/24/2009 | EP2072522A1 Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes |
| 06/24/2009 | EP2072521A1 Octahedral metal (III) polypyridyl complexes and their use in prevention and treatment of cancer |
| 06/24/2009 | EP2072519A1 Diaryl ketimine derivative |
| 06/24/2009 | EP2072518A1 Stable Amorphous Form of Pemextred Disodium |
| 06/24/2009 | EP2072516A1 Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists |
| 06/24/2009 | EP2072515A1 Substituted quinazolidines for antidiabetic treatment |
| 06/24/2009 | EP2072514A1 1(2)H-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents |
| 06/24/2009 | EP2072513A1 A cyano piperidinyl-phenil-oxazolidinone and use thereof |
| 06/24/2009 | EP2072510A1 Crystalline form of azelastine |
| 06/24/2009 | EP2072509A1 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents |
| 06/24/2009 | EP2072502A1 Sulfoximide substituted chinolin and chinazolin derivatives as kinase inhibitors |
| 06/24/2009 | EP2072494A1 Cosmetic and pharmaceutical compositions |
| 06/24/2009 | EP2072082A2 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3 sulfonamide as analgetic agent |
| 06/24/2009 | EP2072052A1 Prevention of opportunistic infections in immune-compromised subjects |
| 06/24/2009 | EP2072051A1 Combination of azelastine and mometasone |
| 06/24/2009 | EP2072050A1 Compounds with anti-emetic effect |
| 06/24/2009 | EP2072049A2 Solid valsartan pharmaceutical compositions |
| 06/24/2009 | EP2072048A1 Use of pinolenic acid for the treatment of obesity |
| 06/24/2009 | EP2072047A1 Therapeutic agent for opthalmic disease |
| 06/24/2009 | EP2072046A1 Use of a hydrocarbon-containing preparation for preventing or treating cardiac-circulatory diseases, diabetes, osteoporosis and chronic liver failure |
| 06/24/2009 | EP2072043A2 Mesalazine tablet |
| 06/24/2009 | EP2072042A1 Active pharmaceutical ingredient on solid support, amorphous and with improved solubility |
| 06/24/2009 | EP2072041A1 Film-coated tablets containing drospirenone as active agent and method for the preparation thereof |
| 06/24/2009 | EP1957450B1 Serotonin transporter (sert) inhibitors |
| 06/24/2009 | EP1954698B1 Spirocyclic compounds as hdac inhibitors |
| 06/24/2009 | EP1951261A4 Compositions and methods for treating inflammatory disorders |
| 06/24/2009 | EP1948654B1 5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension |
| 06/24/2009 | EP1874781B1 Dihydrothienopyrimidines for the treatment of inflammatory diseases |
| 06/24/2009 | EP1874278B1 Compositions containing micronized tanaproget |
| 06/24/2009 | EP1863812A4 Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| 06/24/2009 | EP1844004B1 Quinazoline derivates as antiviral agents |
| 06/24/2009 | EP1841332B1 Thickener composition for dysphagia patients |
| 06/24/2009 | EP1781614B1 Compounds which potentiate glutamate receptor and uses thereof in medicine |
| 06/24/2009 | EP1763526B1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors |
| 06/24/2009 | EP1725224A4 Methods and compositions comprising non-peptide small molecules that solubilize beta amyloid peptide fiber |
| 06/24/2009 | EP1713769B1 Amorphous tamsulosin hydrochloride |
| 06/24/2009 | EP1686959B1 Pharmaceutical formulations employing short-chain sphingolipids and their use |
| 06/24/2009 | EP1660131B1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 06/24/2009 | EP1651246A4 Method for promoting bone growth |
| 06/24/2009 | EP1643846A4 Method for treatment of sores and lesions of the skin |
| 06/24/2009 | EP1641485A4 Inhibition of sars coronavirus infection with clinically approved antiviral drugs |
| 06/24/2009 | EP1620093B1 Pesticidal (dihalopropenyl) phenylalkyl substituted benzoxazole and benzothiazole derivatives |
| 06/24/2009 | EP1611109A4 Novel quinazoline derivatives and methods of treatment related to the use thereof |
| 06/24/2009 | EP1575522B1 Methods for treating pain by administering an antagonist antibody against the nerve growth factor and an opioid analgesic and compositions containing the same |
| 06/24/2009 | EP1558567B1 Novel amide compounds with mch antagonistic effect and medicaments comprising said compounds |
| 06/24/2009 | EP1556026B1 Novel pharmaceutical formulations of modafinil |
| 06/24/2009 | EP1499746A4 Method to inhibit cell growth using oligonucleotides |
| 06/24/2009 | EP1483247B1 Aryl substituted pyrimidines and the use thereof |
| 06/24/2009 | EP1445258B1 Activator for peroxisome proliferator-activated receptor delta |
| 06/24/2009 | EP1385522B1 Combination comprising a signal transduction inhibitor and an epothilone derivative |
| 06/24/2009 | EP1339709B1 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 06/24/2009 | EP1303591B1 Masp-2, a complement-fixing enzyme, and uses for it |
| 06/24/2009 | EP1284977B1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 06/24/2009 | EP1205559B1 Method for detecting pathogenic microorganisms and antimicrobial agents, method for evaluating the drug effect of antimicrobial agents, and antimicrobial agents |
| 06/24/2009 | EP1152761B1 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| 06/24/2009 | EP1131106B1 Compositions and methods for producing vascular occlusion |
| 06/24/2009 | CN101466686A C-FMS kinase inhibitor |
| 06/24/2009 | CN101466386A Augmentation of titer for vaccination in animals |
| 06/24/2009 | CN101466385A Delayed-release glucocorticoid treatment of rheumatoid disease |
| 06/24/2009 | CN101466384A Osmotic drug delivery system comprising release enhancing agent |
| 06/24/2009 | CN101466383A Prolonged improvement of renal function comprising infrequent administration of an AAIRA |
| 06/24/2009 | CN101466382A Substituted 8-amino-3-pyridyl]xanthines |
| 06/24/2009 | CN101466381A Stereoselective reduction of a morphinone |
| 06/24/2009 | CN101466380A Methods and compositions for the treatment of parkinson's disease |
| 06/24/2009 | CN101466379A Stable laquinimod preparations |
| 06/24/2009 | CN101466378A Piperidine derivatives useful for treating osteoarthritis and osteoartrosis |
| 06/24/2009 | CN101466377A Thiazolidinedione derivatives as PI3 kinase inhibitors |
| 06/24/2009 | CN101466376A CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients |
| 06/24/2009 | CN101466375A Substituted azaspiro derivatives |
| 06/24/2009 | CN101466374A Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1(VR1) receptors |
| 06/24/2009 | CN101466373A A suspension comprising benzimidazole carbamate and a polysorbate |
| 06/24/2009 | CN101466372A Therapeutic delivery of carbon monoxide |
| 06/24/2009 | CN101466371A Stabilized pharmaceutical compositions comprising fesoterodine |
| 06/24/2009 | CN101466370A Nanoemulsion vaccines |
| 06/24/2009 | CN101466369A Oral patch with salt of glycyrrhetinic acid water soluble at human mouth temperatures |
| 06/24/2009 | CN101466368A Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury |
| 06/24/2009 | CN101466367A Method for treating renal disease |
| 06/24/2009 | CN101466366A Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| 06/24/2009 | CN101466365A Method for enhancing cognitive function |
| 06/24/2009 | CN101466364A Intranasal administration of ketamine to treat depression |
| 06/24/2009 | CN101466363A Ah receptor antagonists |
| 06/24/2009 | CN101466362A Oral composition with an antiageing effect on the skin |
| 06/24/2009 | CN101466357A Direct cellular energy delivery system |
| 06/24/2009 | CN101461823A Composition with function for promoting lead-expelling and method for preparing the same |
| 06/24/2009 | CN101461822A Application of chitosan oligosaccharide in preparing medicament for sobering up and protecting liver |
| 06/24/2009 | CN101461821A Compound oral medicament composition for treating respiratory diseases of pig and cattle |
| 06/24/2009 | CN101461820A Application of mangiferin in preparing anti-influenza virus medicament |
| 06/24/2009 | CN101461819A Use of mangiferin calcium salt as peroxisome proliferator-activated receptor agonist |
| 06/24/2009 | CN101461818A Pharmaceutical composition for treating atherosclerosis disease and use |
| 06/24/2009 | CN101461817A Use of 1,2,3,4,6-five-O-gallnut acyl radical-b-D-glucose |